News for Kronos Bio, Inc. (KRON)

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

PR NewswireNEW YORK, May 6, 2025 NEW YORK, May 6, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

NEW YORK, May 03, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

PR NewswireNEW YORK, May 1, 2025 NEW YORK, May 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. C

Kronos Bio set for acquisition by Concentra Biosciences at $0.57 per share. Analysts maintain a $2.25 target, suggesting a substantial upside. Curren

**media[611669]**

Overview of the Recent Transaction On April 20, 2020, Wildcat Capital Management, LLC (Trades, Portfolio) made a significant move by acquiring 6,070,588 shares

Revenue: $2.27 million for Q4 2024, slightly below the estimated $2.42 million.Earnings Per Share (EPS): Reported at -$0.43, missing the estimated EPS of -$0.3

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ( KRON), a biopharmaceutical company, today reported fourth quart

Kronos Bio announces major leadership changes and an 83% workforce reduction as part of a strategic overhaul, with stock gaining in premarket.

”“ Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO ”“ ”“ Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim C

Kronos Bio (KRON) stock gains as company appoints interim CEO Deborah Knobelman amid plans to cut 83% of workforce. Read more here.

Kronos Bio (KRON) has been downgraded by Piper Sandler and TD Cowen following news that the company has halted development of its lead drug candidate. Read more here.

Kronos Bio (KRON) delivered earnings and revenue surprises of 11.54% and 35.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[456873]**

– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –...

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors